Congratulations Kristian! @lundsuniversitet.bsky.social @lunduniversity-med.bsky.social

www.nature.com/articles/s41...

Finally, we send our gratitude to all funders
@lund-university.bsky.social , @vetenskapsradet.bsky.social @kawresearch.bsky.social, Cancerfonden, Region Skåne, The Göran Gustafsson Foundation, The Mats Paulsson Foundations, Cancera, The Crafoord Foundation, and the Fru Berta Kamprad Foundation.
6/6

Incredible skills, knowledge, endurance, passion, and joy went into the making of this study by main authors @matteobocci.bsky.social, Mehrnaz Safaee-Talkhoncheh, and Jonas Sjölund. We also thank all co-authors, and especially acknowledge the work of undergraduate and graduate students.
5/6

Based on our work, the combination of ALK1 inhibition with immune checkpoint blockade is suggested as a rational treatment regimen; clinical studies by pharmaceutical industry provide initial support for this proposition (pmc.ncbi.nlm.nih.gov/articles/PMC...).
4/6

ALK1 inhibition acted in a multimodal manner to suppress breast cancer metastatic dissemination to the lung by: 1) Interfering with the differentiation and release of monocytes in the bone marrow and 2) Reducing the mobilization of immunosuppressive macrophages across the endothelial barrier.
3/6

When we set out on this journey, we did not expect to delve into tumor immunology, but the unanticipated expression of ALK1 on a subset of highly immunosuppressive macrophages led us to detail a role for ALK1 at the crossroads between tumor angiogenesis and immunity.
2/6

Kristian Pietras @kpietraslab.bsky.social at Lund University @lunduniversity.bsky.social will oversee DC4 who will work on the suppression of metastatic dissemination through precision targeting of cancer-associated fibroblast niches

adaptmet.eu